ALDX Stock Overview
A biotechnology company, develops and commercializes medicines for immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.36 |
| 52 Week High | US$7.81 |
| 52 Week Low | US$1.42 |
| Beta | 1.45 |
| 11 Month Change | 38.50% |
| 3 Month Change | 41.42% |
| 1 Year Change | -27.27% |
| 33 Year Change | -40.84% |
| 5 Year Change | 21.54% |
| Change since IPO | -25.56% |
Recent News & Updates
Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Jun 21
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Shareholder Returns
| ALDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.3% | 4.7% | 3.1% |
| 1Y | -27.3% | 15.1% | 24.9% |
Return vs Industry: ALDX underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: ALDX underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| ALDX volatility | |
|---|---|
| ALDX Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ALDX's share price has been volatile over the past 3 months.
Volatility Over Time: ALDX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 10 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| ALDX fundamental statistics | |
|---|---|
| Market cap | US$319.69m |
| Earnings (TTM) | -US$37.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.4x
P/E RatioIs ALDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.87m |
| Earnings | -US$37.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 15.5% |
How did ALDX perform over the long term?
See historical performance and comparison